Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Remi Mito"'
Autor:
Eri Matsubara, Yoshihiro Komohara, Shigeyuki Esumi, Yusuke Shinchi, Shiho Ishizuka, Remi Mito, Cheng Pan, Hiromu Yano, Daiki Kobayashi, Yukio Fujiwara, Koei Ikeda, Takuro Sakagami, Makoto Suzuki
Publikováno v:
Cancers, Vol 14, Iss 18, p 4374 (2022)
Osteopontin, also called secreted phosphoprotein 1 (SPP1), is a multifunctional secreted phosphorylated glycoprotein. SPP1 is also expressed in tumor cells, and many studies demonstrated that a high level of circulating SPP1 is correlated with a poor
Externí odkaz:
https://doaj.org/article/18faf1e987114e258a35443001119a87
Autor:
Yoshiaki Zaizen, Yuri Tachibana, Yukio Kashima, Andrey Bychkov, Kazuhiro Tabata, Kyoko Otani, Yoshiaki Kinoshita, Yasuhiko Yamano, Kensuke Kataoka, Kazuya Ichikado, Masaki Okamoto, Tomoo Kishaba, Remi Mito, Koichi Nishimura, Mari Yamasue, Kazuki Nabeshima, Kentaro Watanabe, Yasuhiro Kondoh, Junya Fukuoka
Publikováno v:
Journal of Clinical Medicine, Vol 10, Iss 5, p 895 (2021)
The pathogenesis of pleuroparenchymal fibroelastosis (PPFE), a rare interstitial lung disease, remains unclear. Based on previous reports and our experience, we hypothesized that alveolar epithelial denudation (AED) was involved in the pathogenesis o
Externí odkaz:
https://doaj.org/article/d1d4d6491d844f628dd5b06d9044cbe5
Autor:
Koichi Saruwatari, Ryo Sato, Shunya Nakane, Shinya Sakata, Koutaro Takamatsu, Takayuki Jodai, Remi Mito, Yuko Horio, Sho Saeki, Yusuke Tomita, Takuro Sakagami
Publikováno v:
Cancers, Vol 11, Iss 2, p 140 (2019)
Background: Anti-programmed cell death 1 (PD-1) monoclonal antibodies (Abs) unleash an immune response to cancer. However, a disruption of the immune checkpoint function by blocking PD-1/PD-ligand 1(PD-L1) signaling may trigger myasthenia gravis (MG)
Externí odkaz:
https://doaj.org/article/c9bb57031f1d464c9b3b22d78764ac22
Autor:
HIROYUKI YAMADA, RIN YAMADA, YOSHIHIRO KOMOHARA, REMI MITO, KAZUCHIKA NISHITSUJI, HIROMU YANO, YUKIO FUJIWARA, KOEI IKEDA, MAKOTO SUZUKI
Publikováno v:
Cancer Diagnosis & Prognosis; Mar/Apr2024, Vol. 4 Issue 2, p204-208, 5p
Autor:
Remi Mito, Toyohisa Iriki, Yukio Fujiwara, Cheng Pan, Tsuyoshi Ikeda, Toshihiro Nohara, Makoto Suzuki, Takuro Sakagami, Yoshihiro Komohara
Publikováno v:
Human Cell. 36:1068-1080
Tumor-associated macrophage (TAM)-derived IL-6 is involved in small-cell lung cancer (SCLC) progression and chemoresistance via the activation of signal transducer and activator of transcription 3 (STAT3) in the tumor microenvironment. This study aim
Autor:
Yoichi Saito, Yukio Fujiwara, Yusuke Shinchi, Remi Mito, Yuji Miura, Tomoya Yamaguchi, Koei Ikeda, Shinji Urakami, Yuta Nakashima, Takuro Sakagami, Makoto Suzuki, Yasuhiko Tabata, Yoshihiro Komohara
Publikováno v:
Cancer Science. 113:3255-3266
Programmed death (PD)-1/PD-ligand 1 (PD-L1) antibodies have shown an intense clinical effect in some patients with PD-L1
Autor:
Yuji Miura, Takanobu Motoshima, Toshiki Anami, Hiromu Yano, Remi Mito, Cheng Pan, Shinji Urakami, Keiichi Kinowaki, Hirotake Tsukamoto, Ryoma Kurahashi, Yoji Murakami, Junji Yatsuda, Yukio Fujiwara, Tomomi Kamba, Yoshihiro Komohara
Publikováno v:
Microbiology and Immunology.
Autor:
Yusuke Shinchi, Shiho Ishizuka, Yoshihiro Komohara, Eri Matsubara, Remi Mito, Cheng Pan, Daiki Yoshii, Kimihiro Yonemitsu, Yukio Fujiwara, Koei Ikeda, Koji Tamada, Takuro Sakagami, Makoto Suzuki
Publikováno v:
Cancer Immunology, Immunotherapy. 71:2645-2661
Programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) are target molecules for immunotherapy in non-small cell lung cancer. PD-L1 is expressed not only in cancer cells, but also on macrophages, and has been suggested to contribute to macrophage-me
Autor:
Yoshihiro Komohara, Toshiyuki Shima, Masayuki Shimoda, Remi Mito, Yusuke Shinchi, Koei Ikeda, Makoto Suzuki, Takuro Sakagami, Eri Matsubara, Yae Kanai, Yukio Fujiwara
Publikováno v:
Pathology International. 71:666-673
CD163 is one of the scavenger receptors expressed on macrophages. However, several immunohistochemical studies have demonstrated that CD163 is also detected on cancer cells, and is associated with a poor prognosis. In the present study, we detected C
Autor:
Yuji Miura, Takanobu Motoshima, Toshiki Anami, Hiromu Yano, Remi Mito, Shinji Urakami, Keiichi Kinowaki, Hirotake Tsukamoto, Ryoma Kurahashi, Yoji Murakami, Junji Yatsuda, Yukio Fujiwara, Tomomi Kamba, Yoshihiro Komohara
Publikováno v:
Cancer Research. 83:4326-4326
Background: Immune checkpoint inhibitors (ICIs) have recently improved the prognosis of various cancers. In contrast, some immune-related adverse events (irAEs) caused by ICIs are fatal and have become problematic. The pathogenesis of irAEs remains u